These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 9340186)

  • 21. Serotonergic approaches in the development of novel antipsychotics.
    Jones CA; McCreary AC
    Neuropharmacology; 2008 Nov; 55(6):1056-65. PubMed ID: 18621404
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Pharmacology of second-generation antipsychotics: a validity of the serotonin-dopamine hypothesis].
    Kuroki T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2004 Oct; 24(5):257-64. PubMed ID: 15658501
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Physiological and therapeutic relevance of constitutive activity of 5-HT 2A and 5-HT 2C receptors for the treatment of depression.
    Berg KA; Harvey JA; Spampinato U; Clarke WP
    Prog Brain Res; 2008; 172():287-305. PubMed ID: 18772038
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [New therapeutic possibilities with drugs affecting serotonin receptors].
    Spigset O
    Tidsskr Nor Laegeforen; 1992 May; 112(13):1700-4. PubMed ID: 1509427
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dopamine and serotonin interactions in the prefrontal cortex: insights on antipsychotic drugs and their mechanism of action.
    Di Pietro NC; Seamans JK
    Pharmacopsychiatry; 2007 Dec; 40 Suppl 1():S27-33. PubMed ID: 18080940
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cognitive dysfunction in neuropsychiatric disorders: selected serotonin receptor subtypes as therapeutic targets.
    Terry AV; Buccafusco JJ; Wilson C
    Behav Brain Res; 2008 Dec; 195(1):30-8. PubMed ID: 18241938
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Recent advances in neuropsychopharmacology of the central serotonin receptor].
    Yamawaki S; Hayakawa H
    Yakubutsu Seishin Kodo; 1992 Apr; 12(2):43-54. PubMed ID: 1441762
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors.
    Millan MJ
    J Pharmacol Exp Ther; 2000 Dec; 295(3):853-61. PubMed ID: 11082417
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serotonin decreases generation of dopaminergic neurons from mesencephalic precursors via serotonin type 7 and type 4 receptors.
    Parga J; Rodriguez-Pallares J; Muñoz A; Guerra MJ; Labandeira-Garcia JL
    Dev Neurobiol; 2007 Jan; 67(1):10-22. PubMed ID: 17443768
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The involvement of 5-HT1a serotonin receptors in the pathophysiology and pharmacotherapy of schizophrenia].
    Maćkowiak M; Czyrak A; Wedzony K
    Psychiatr Pol; 2000; 34(4):607-21. PubMed ID: 11059260
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Conventional versus novel antipsychotics: changing concepts and clinical implications.
    Remington G; Chong SA
    J Psychiatry Neurosci; 1999 Nov; 24(5):431-41. PubMed ID: 10586534
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tolerability and safety aspects of mirtazapine.
    Nutt DJ
    Hum Psychopharmacol; 2002 Jun; 17 Suppl 1():S37-41. PubMed ID: 12404669
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serotonergic modulation of dopamine neurotransmission: a mechanism for enhancing therapeutics in schizophrenia.
    Haleem DJ
    J Coll Physicians Surg Pak; 2006 Aug; 16(8):556-62. PubMed ID: 16899192
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The serotonin hypothesis of depression].
    Lesch KP; Beckmann H
    Fortschr Neurol Psychiatr; 1990 Nov; 58(11):427-38. PubMed ID: 2177721
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Potential value of 5-HT2 receptor antagonists in the treatment of dysthymic disorders].
    Sechter D; Bonin B; Bizouard P
    Encephale; 1992 Dec; 18 Spec No 5():753-4. PubMed ID: 1342678
    [No Abstract]   [Full Text] [Related]  

  • 36. Serotonin-specific drugs for anxiety and depressive disorders.
    Charney DS; Krystal JH; Delgado PL; Heninger GR
    Annu Rev Med; 1990; 41():437-46. PubMed ID: 2139556
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Perspectives on the role of serotonergic mechanisms in the pharmacology of schizophrenia.
    Busatto GF; Kerwin RW
    J Psychopharmacol; 1997; 11(1):3-12. PubMed ID: 9097883
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of serotonin in depression and anxiety.
    Baldwin D; Rudge S
    Int Clin Psychopharmacol; 1995 Jan; 9 Suppl 4():41-5. PubMed ID: 7622823
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The benefits and risks of 5-HT uptake inhibitors in depression.
    Montgomery SA
    Br J Psychiatry Suppl; 1988 Sep; (3):7-10. PubMed ID: 2471570
    [No Abstract]   [Full Text] [Related]  

  • 40. Update in the treatment of schizophrenia.
    Katz I; Kac M
    Aust Fam Physician; 1993 Apr; 22(4):577-80, 584-5, 590-7. PubMed ID: 8481123
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.